Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Olsalazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 3/20 | 0.54 |
| ▸ | PTGS2 known ✓ | P35354 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | BLVRB | P30043 | 2/20 | 0.66 |
| ▸ | PDE4A | P27815 | 1/20 | 0.66 |
| ▸ | KDR | P35968 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.58 |
| ▸ | APP | P05067 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | PHLPP2 | Q6ZVD8 | 5/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Olsalazine SCHEMBL29454399 | 1.00 | MEN1 (0.66) | MEN1KMT2ABLVRBPDE4AKDR | |
| Olsalazine SCHEMBL29767 | 1.00 | MEN1 (0.66) | MEN1KMT2ABLVRBPDE4AKDR | |
| SCHEMBL10784910 | 0.94 | MEN1 (0.59) | MEN1KMT2ABLVRBPDE4AKDR | |
| Chrysamine G SCHEMBL15818024 | 0.93 | TDP1 (0.70) | MEN1KMT2ABLVRBPDE4AKDR | |
| Olsalazine SCHEMBL15201080 | 0.93 | MEN1 (0.79) | MEN1KMT2ABLVRBPDE4AKDR | |
| SCHEMBL29950230 | 0.91 | MEN1 (0.61) | MEN1KMT2ABLVRBPDE4AKDR | |
| SCHEMBL27985065 | 0.91 | MEN1 (0.61) | MEN1KMT2ABLVRBPDE4AKDR | |
| SCHEMBL1614891 | 0.90 | TDP1 (0.57) | MEN1KMT2ABLVRBPDE4AKDR | |
| SCHEMBL27727543 | 0.87 | PHLPP2 (0.60) | MEN1KMT2ABLVRBPDE4AKDR | |
| SCHEMBL428681 | 0.87 | PLCG1 (0.61) | MEN1KMT2ABLVRBPDE4AKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5500668-A | INK JET PRINTING | XEROX CORPORATION (US) | 1996-03-19 | — | — | US | claimed |
| US-11905562-B2 | Serotonin transporter gene and treatment of opioid-related disorders | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-02-20 | — | — | US | disclosed |
| US-20210301346-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2021-09-30 | — | — | US | disclosed |
| CN-112805016-A | Matrix-binding vesicles (MBVs) comprising IL-33 and uses thereof | 联邦高等教育系统匹兹堡大学 | 2021-05-14 | — | — | CN | disclosed |
| CN-110799186-A | Compositions and methods for treating inflammatory diseases | 以色列国家农业部、农村发展农业研究组织·沃尔卡尼中心 | 2020-02-14 | — | — | CN | disclosed |
| CN-110678543-A | In vitro culture system and method of use | 耶达研究及发展有限公司 | 2020-01-10 | — | — | CN | disclosed |
| US-20100015111-A1 | Methods And Kits For The Treatment Inhibition, And Maintenance Of Gastrointestinal Disorders | WARNER CHILCOTT COMPANY, LLC | 2010-01-21 | — | — | US | disclosed |
| US-20060205930-A1 | Process for the preparation of aromatic azo-compounds | GENERICS [UK] LIMITED (GB) | 2006-09-14 | — | — | US | disclosed |
| US-7091327-B2 | Treating aromatic amino-compounds with hydrogen peroxide and acetic acid, followed by sulphuric acid, to yield aromatic azo-compound or salt | GENERICS [UK] LIMITED (GB) | 2006-08-15 | — | — | US | disclosed |
| US-20040132982-A1 | Process for the preparation of aromatic azo-compounds | GENERICS [UK] LIMITED | 2004-07-08 | — | — | US | disclosed |
| EP-0331471-B1 | HIGH MOLECULAR WEIGHT PRODRUG DERIVATIVES OF ANTIINFLAMMATORY DRUGS | Larsen, Claus Selch (DK) | 1992-12-16 | — | — | EP | disclosed |
| EP-0483429-A1 | Biodegradable polymer compositions | NOVA PHARMACEUTICAL CORPORATION (US) | 1992-05-06 | — | — | EP | disclosed |
| US-4999417-A | Drug carriers for controlled release | NOVA PHARMACEUTICAL CORPORATION (US) | 1991-03-12 | — | — | US | disclosed |
| EP-0331471-A1 | High molecular weight prodrug derivatives of antiinflammatory drugs | Larsen, Claus Selch (DK) | 1989-09-06 | — | — | EP | disclosed |
| US-4559330-A | Use of 3,3'-azo-bis-(6-hydroxy benzoic acid) as a drug and pharmaceutical compositions containing the same | PHARMACIA AB (SE) | 1985-12-17 | — | — | US | disclosed |
| US-4528367-A | Method and intermediates for preparing high purity 3,3'-azo-bis-(6-hydroxy benzoic acid) | PHARMACIA AB (SE) | 1985-07-09 | — | — | US | disclosed |
| EP-0036636-B1 | A METHOD AND INTERMEDIATES FOR PREPARING 3,3'-AZO-BIS-(6-HYDROXY BENZOIC ACID) | PHARMACIA AB (SE) | 1984-02-15 | — | — | EP | disclosed |
| EP-0036637-B1 | USE OF 3,3'-AZO-BIS-(6-HYDROXY BENZOIC ACID) AS A DRUG AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | PHARMACIA AB (SE) | 1983-10-19 | — | — | EP | disclosed |
| EP-0036637-A1 | Use of 3,3'-azo-bis-(6-hydroxy benzoic acid) as a drug and pharmaceutical compositions containing the same | PHARMACIA AB (SE) | 1981-09-30 | — | — | EP | disclosed |
| EP-0036636-A1 | A method and intermediates for preparing 3,3'-azo-bis-(6-hydroxy benzoic acid) | PHARMACIA AB (SE) | 1981-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11905562-B2 | Serotonin transporter gene and treatment of opioid-related disorders | SLC6A4, SLC6A3, SLC6A2 | PTGS1 962/4885PTGS2 892/4885MEN1 4859/4885 |
| US-20060205930-A1 | Process for the preparation of aromatic azo-compounds | PAH, TYR, DDC | PTGS1 3449/4885PTGS2 3396/4885MEN1 2664/4885 |
| US-20100015111-A1 | Methods And Kits For The Treatment Inhibition, And Maintenance Of Gastrointestinal Disorders | SI, VIP, ALPI | PTGS1 775/4885PTGS2 1780/4885MEN1 764/4885 |
| US-20210301346-A1 | SEROTONIN TRANSPORTER GENE AND TREATMENT OF OPIOID-RELATED DISORDERS | SLC6A4, SLC6A3, SLC6A2 | PTGS1 962/4885PTGS2 892/4885MEN1 4859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.